Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin
SourceCancer Management and Research, 8, (2016), pp. 95-104
Article / Letter to editor
Display more detailsDisplay less details
Cancer Management and Research
SubjectRadboudumc 9: Rare cancers RIHS: Radboud Institute for Health Sciences
Soft-tissue sarcomas (STS) are a heterogeneous group of rare solid tumors of mesenchymal origin. This paper reviews the current status of systemic treatment in advanced and metastatic soft tissue sarcomas, with an emphasis on trabectedin. Trabectedin is a unique type of chemotherapeutic agent with multiple potential mechanisms of action. We discuss the putative mechanisms, as well as the toxicity and administration schedules of trabectedin, followed by its efficacy in first-line systemic therapy and beyond first-line systemic therapy.
This item appears in the following Collection(s)
- Academic publications 
- Electronic publications 
- Faculty of Medical Sciences 
- Open Access publications 
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.